Compare XGN & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XGN | COYA |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 102.7M |
| IPO Year | 2014 | 2022 |
| Metric | XGN | COYA |
|---|---|---|
| Price | $8.46 | $4.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $10.14 | ★ $15.21 |
| AVG Volume (30 Days) | ★ 273.4K | 144.3K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | $11.02 | N/A |
| Revenue Next Year | $10.28 | $387.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $2.59 | $3.71 |
| 52 Week High | $12.23 | $7.75 |
| Indicator | XGN | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 49.88 |
| Support Level | $7.81 | $4.42 |
| Resistance Level | $8.89 | $5.17 |
| Average True Range (ATR) | 0.42 | 0.25 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 58.33 | 23.08 |
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.